GLP-1 oral drugs list: every pill available in 2026

Three oral GLP-1 drugs are available in United States right now. Two are approved for weight loss. One is approved for type 2 diabetes but sometimes used off label for weight management.

Here is each one:

Wegovy pill (oral semaglutide 25 mg)

This is first oral GLP-1 approved specifically for weight loss. The FDA approved it in December 2025. It launched in US pharmacies in January 2026.

It's the same molecule as injectable Wegovy and Ozempic. The difference is delivery. You swallow a tablet instead of injecting.

What it treats: Chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with a weight related condition. Also approved to reduce risk of heart attacks and strokes in adults with obesity and established cardiovascular disease.

How you take it: One tablet daily, first thing in morning. Empty stomach. No more than 4 ounces of plain water. Wait 30 minutes before eating, drinking, or taking other medications.

Dose steps: 1.5 mg for 4 weeks, then 4 mg, then 9 mg, then 25 mg. Full escalation takes about 4 months.

Weight loss: 13.6% average at 64 weeks in OASIS 4 trial. With full adherence, 16.6%.

Cost: $149/month self pay for starting dose through NovoCare. With commercial insurance and savings card, copay can be as low as $0 to $25/month.

Storage: Room temperature. No refrigeration needed. This is a real advantage over injectable pens.

Foundayo (orforglipron)

Foundayo is newest oral GLP-1. The FDA approved it on April 1, 2026. It's made by Eli Lilly, the same company behind Mounjaro and Zepbound.

The big difference from oral Wegovy: no food or water restrictions. You can take it any time of day, with or without food. That's because orforglipron is a small molecule, not a peptide. It doesn't need special absorption technology that oral semaglutide requires.

What it treats: Chronic weight management in adults with obesity or overweight with a weight related condition.

How you take it: One tablet daily. Any time. No fasting required.

Dose steps: 0.8 mg, then 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and up to 17.2 mg. Escalation every 4 weeks.

Weight loss: About 12.4% average at highest dose over 72 weeks in ATTAIN-1 trial. Less than oral Wegovy, but still meaningful.

Cost: $149/month self pay for lowest dose. With Lilly savings card, as low as $25/month. Medicare Part D patients may pay $50/month starting July 2026.

Storage: Room temperature.

Rybelsus (oral semaglutide 7 mg and 14 mg)

Rybelsus has been available since 2019. It was first oral GLP-1 drug approved by FDA, but only for type 2 diabetes. It is not approved for weight loss.

Some doctors prescribe it off-label for weight management. The weight loss at these lower doses is modest, typically 3% to 5% of body weight. That's far less than Wegovy pill or Foundayo.

What it treats: Type 2 diabetes. Weight loss use is off label.

How you take it: Same timing rules as Wegovy pill. Empty stomach, small sip of water, wait 30 minutes.

Dose steps: 3 mg for 30 days (not a treatment dose, just for adjustment), then 7 mg, then 14 mg.

Weight loss: 3% to 5% average at the 14 mg dose in diabetes trials. Not tested at higher doses for weight loss.

Cost: Typically $900 to $1,000/month without insurance. Less with savings programs.

How do the oral GLP-1 drugs compare?

The differences come down to four things.

Weight loss: Wegovy pill produces most (13-17%). Foundayo produces moderate weight loss (about 12%). Rybelsus produces modest weight loss (3-5%).

Convenience: Foundayo wins here. No timing restrictions. Wegovy pill and Rybelsus both need empty stomach and 30 minute wait.

Approval: Wegovy pill and Foundayo are both approved for weight loss. Rybelsus is not.

Cost: Wegovy pill and Foundayo both start at $149/month self pay. Rybelsus is more expensive without insurance but may be covered by diabetes specific plans.

If cost is a factor, comparing oral options against injectable pricing can help. Our articles on Mounjaro vs Ozempic costand Ozempic cost at Costco without insurance cover the injectable side of equation.

Are there other oral GLP-1 drugs coming?

Yes. Several are in clinical trials.

Amycretin from Novo Nordisk is a dual GLP-1/amylin pill. Phase 2 data showed about 13% weight loss in just 12 weeks, which is faster than any approved oral GLP-1. Phase 3 trials are underway.

Danuglipron from Pfizer is another small molecule oral GLP-1. It ran into liver safety concerns in earlier testing. Pfizer is still studying a modified release version.

Ecnoglutide and other oral candidates are in earlier stage development from smaller companies.

The pipeline is active. But three drugs listed above are only oral GLP-1 options you can actually get a prescription for today.

Which oral GLP-1 should you ask your doctor about?

If you want the most weight loss from a pill, ask about Wegovy pill. It has strongest data and FDA approval for both weight loss and cardiovascular risk reduction.

If 30 minute fasting rule is a dealbreaker for you, ask about Foundayo. Slightly less weight loss, but much simpler to fit into a daily routine.

If you have type 2 diabetes and want to try an oral GLP-1, Rybelsus is established option. But if weight loss is your main goal, the newer drugs deliver more.

Your doctor can look at your insurance coverage, your health history, and your daily routine and help you pick right one.